Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 11038 pages

Showing 51 - 100


breast cancer
immunotherapy

KEYNOTE-522: A Biomarker Resource for PD-1 Inhibition in Early Triple-Negative Breast Cancer

In the phase III KEYNOTE-522 trial reported in The New England Journal of Medicine and reviewed in this issue of The ASCO Post, Schmid et al1 found that the addition of pembrolizumab to neoadjuvant chemotherapy in stage II or III triple-negative breast cancer significantly improved the pathologic...

breast cancer

Expert Point of View: Virginia Kaklamani, MD, DSc, and Minetta Liu, MD

Virginia Kaklamani, MD, DSc, Professor of Medicine and Head of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, moderated a press conference where Milan Radovich, PhD, reported the robust ability of circulating tumor DNA (ctDNA) and circulating tumor cells to predict...

hematologic malignancies
lymphoma
immunotherapy

Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers

Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...

gynecologic cancers

Addition of Olaparib to Bevacizumab Maintenance in Advanced Ovarian Cancer: PAOLA-1 Trial

As reported in The New England Journal of Medicine by Isabelle Ray‑Coquard, MD, PhD, of the Centre Leon Berard, University Claude Bernard Lyon 1 and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Paris, and colleagues, the phase III PAOLA-1 trial has shown a...

Timothy Chan, MD, PhD, Named Director of Cleveland Clinic’s Center for Immunotherapy and Precision Immuno-Oncology

Timothy Chan, MD, PhD, has been appointed Director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic. Dr. Chan will lead the new center to bring together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related...

skin cancer
immunotherapy

Expert Point of View: Omid Hamid, MD

Omid Hamid, MD, Chief of Research/Immuno-Oncology, The Angeles Clinic & Research Institute, and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Center, Los Angeles, commented on these two studies for The ASCO Post. According to Dr. Hamid, the findings for the tumor...

skin cancer
immunotherapy

Novel Treatment Strategies Under Study in Advanced Melanoma

Several novel strategies for the treatment of patients with stage III or IV melanoma showed promise in studies presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.1,2 Vaccine for High-Risk Patients After Resection A tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine was...

gynecologic cancers

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...

issues in oncology

Kimlin T. Ashing, PhD, on Tobacco and Vape Shops in Neighborhoods With Lower-Income and Minority Populations

Kimlin T. Ashing, PhD, of City of Hope National Medical Center, discusses analyses that showed neighborhoods with lower-income and minority populations had a greater number of tobacco and vape shops, increased use of electronic nicotine delivery systems, and lower-priced tobacco products. This...

solid tumors
immunotherapy

Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab

Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed preliminary antitumor activity as a monotherapy and in combination with nivolumab in a variety of heavily pretreated patients with...

skin cancer
immunotherapy

Grant A. McArthur, MBBS, PhD, on Melanoma: IMspire150 Trial of Atezolizumab, Cobimetinib, and Vemurafenib

Grant A. McArthur, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses phase III results from a study of previously untreated patients with BRAF V600 mutation–positive advanced melanoma. His team evaluated whether combining vemurafenib and cobimetinib with atezolizumab improved the...

breast cancer
immunotherapy

Steven J. O’Day, MD, on Triple-Negative Breast Cancer: Clinical Benefit With Pembrolizumab Plus Imprime PGG

Steven J. O’Day, MD, of the John Wayne Cancer Institute, discusses phase II results for the combination of pembrolizumab with a novel innate immune activator, Imprime PGG, as second-line treatment for patients with metastatic triple-negative breast cancer ( Abstract CT073).

gynecologic cancers
immunotherapy

FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

On May 8, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of olaparib (Lynparza) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in...

myelodysplastic syndromes

Distinct New MDS Subtype Proposed Based on Presence of Genetic Mutation

In a special report published by Malcovati et al in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) has proposed the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The...

gynecologic cancers

SGO 2020: Wee1 Inhibition in Recurrent Uterine Serous Carcinoma

In a clinical trial in patients with recurrent uterine serous carcinoma, one-third of study participants responded to treatment with the Wee1 inhibitor adavosertib, according to data presented by Liu et al at a virtual session of the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s...

leukemia
covid-19

Laura C. Michaelis, MD: In My Experience Question 5

For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 24, 2020.

leukemia
covid-19

Laura C. Michaelis, MD: In My Experience Question 4

At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia? Recorded April 24, 2020.

leukemia
covid-19

Laura C. Michaelis, MD: In My Experience Question 3

leukemia
covid-19

Laura C. Michaelis, MD: In My Experience Question 2

Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic? Recorded April 24, 2020.

leukemia
covid-19

Laura C. Michaelis, MD: In My Experience Question 1

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia? Recorded April 24, 2020.

lymphoma
covid-19

Mehdi Hamadani, MD: In My Experience Question 6

Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic? Recorded April 21, 2020.

lymphoma
covid-19

Mehdi Hamadani, MD: In My Experience Question 5

For community oncologists treating patients with non-Hodgkin lymphoma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 21, 2020.

covid-19
hematologic malignancies

Mehdi Hamadani, MD: In My Experience Question 4

How have the activities of the Center for International Blood and Marrow Transplant Research been affected by the COVID-19 pandemic? Recorded April 21, 2020.

lymphoma
covid-19

Mehdi Hamadani, MD: In My Experience Question 3

During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma? Recorded April 21, 2020.

lymphoma
covid-19

Mehdi Hamadani, MD: In My Experience Question 2

During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission? Recorded April 21, 2020.

lymphoma
covid-19

Mehdi Hamadani, MD: In My Experience Question 1

Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma? Recorded April 21, 2020.

covid-19

William Dale, MD, PhD, on Best Practices for Special Populations During the COVID-19 Pandemic

William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and reviews best practices for treatment decisions, social distancing, and maintaining emotional health. Recorded April 15, 2020.

lung cancer

FDA Approves Capmatinib for Patients With Metastatic NSCLC With Confirmed MET Exon 14 Skipping

On May 6, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by...

covid-19

Mortality Rate of Patients With Cancer and COVID-19 in a New York Hospital

Patients with cancer who were infected with COVID-19 were much more likely to die from the disease than those without cancer, according to research from physician-researchers at Montefiore Health System and Albert Einstein College of Medicine. Their findings were published by Mehta et al in Cancer...

colorectal cancer
covid-19

Treating Colorectal Cancer in the Time of COVID-19

The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing the risk of COVID-19...

hepatobiliary cancer
immunotherapy

AACR 2020: Atezolizumab Alone or in Combination With Cobimetinib for Biliary Tract Cancer

A randomized multicenter study of a combination of immunotherapy with a targeted therapy improved cancer control for some patients with biliary tract cancer, according to research presented by Yarchoan et al at the American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract...

neuroendocrine tumors
issues in oncology

Issues With Travel Faced by Patients Undergoing Lu-177 Dotatate Radiation Therapy

A team of researchers and patient advocates have addressed the challenges related to traveling after receiving radiation therapy involving Lu-177 dotatate in a study published by Kendi et al in The Journal of Nuclear Medicine. Due to the residual radiation activity of Lu-177 dotatate, some patients ...

breast cancer
immunotherapy

Lajos Pusztai, MD, PhD, on Breast Cancer: I-SPY2 Trial on Durvalumab, Olaparib, and Paclitaxel

Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses study results on durvalumab in combination with olaparib and paclitaxel as neoadjuvant treatment in patients with high-risk HER2-negative stage II/III breast cancer. Compared with patients who received chemotherapy alone, the combination...

multiple myeloma
covid-19

Saad Z. Usmani, MD: In My Experience Question 5

For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 24, 2020.

supportive care

Christopher D'Avella, MD, on Utilizing a Specialized Urgent Care Center for Patients With Cancer

Christopher D'Avella, MD, of Fox Chase Cancer Center, discusses the impact of his institution’s oncologic urgent care center, designed to triage patients and prevent hospital admissions. Patients who presented to the direct referral unit had lower health-care expenses vs those who went to the...

head and neck cancer
survivorship

Pam Baker DeGuzman, PhD, on Assessing Distress During Telemedicine Visits With Rural Survivors of Head and Neck Cancer

Pam Baker DeGuzman, PhD, of the University of Virginia School of Nursing, discusses her study findings on the use of the NCCN Distress Thermometer, which identified and addressed distress in patients treated for head and neck cancer who were then referred to speech pathologists, lymphedema...

colorectal cancer

AI Model Accurately Classifies Colorectal Polyps From Histopathologic Slides

An artificial intelligence (AI) model for automated classification of colorectal polyps could benefit cancer screening programs by improving efficiency, reproducibility, and accuracy, as well as reducing access barriers to pathology services. In a new study published by Wei et al in JAMA Network...

covid-19

FDA Issues Emergency Use Authorization for Remdesivir for Treatment of Severe COVID-19

The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as low...

covid-19

ASCO Survey on Early Impact of COVID-19 on the Performance of Oncology Clinical Trials

An article by Waterhouse et al in JCO Oncology Practice presented results of a recent ASCO survey of clinical programs exploring the early impact of the COVID-19 pandemic on the performance of oncology clinical trials. Results highlighted the numerous issues faced by the programs, steps that are...

multiple myeloma
covid-19

Saad Z. Usmani, MD: In My Experience Question 4

For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19? Recorded April 24, 2020.

multiple myeloma
covid-19

Saad Z. Usmani, MD: In My Experience Question 3

Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma? Recorded April 24, 2020.

multiple myeloma
covid-19

Saad Z. Usmani, MD: In My Experience Question 2

During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma? Recorded April 24, 2020.

covid-19
global cancer care

Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland

Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, talks about the adjustments to cancer care that he and his colleagues have made, how and when they employ telemedicine, and whether the technology could change the future for clinical practice. Filmed April 24, 2020.

multiple myeloma
covid-19

Saad Z. Usmani, MD: In My Experience Question 1

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible? Recorded April 24, 2020.

covid-19
global cancer care

Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19

Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, discusses the concerns his patients with cancer have about exposure to COVID-19 when they come to his institution for care and how he manages their fears. Filmed April 24, 2020.

immunotherapy
covid-19

Negotiating the Obstacles to Conducting Clinical Trials of Immunotherapy During the Coronavirus Pandemic

Coronavirus disease 2019 (COVID-19) is perhaps the biggest challenge health-care systems have ever had to face. As part of a series of interviews The ASCO Post is conducting with oncologists, we talked with Charles G. Drake, MD, PhD, about the impact of COVID-19 on his practice and on the conduct...

multiple myeloma
immunotherapy

FDA Approves Daratumumab and Hyaluronidase-fihj in Multiple Myeloma

On May 1, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adult patients with newly diagnosed, relapsed, or refractory multiple myeloma. This new product allows for subcutaneous dosing of daratumumab. Daratumumab and hyaluronidase-fihj...

leukemia
pancreatic cancer
neuroendocrine tumors
lung cancer
gynecologic cancers
lymphoma

FDA Pipeline: Priority Review in AML, Fast Track Designations for Pancreatic Cancer and Neuroendocrine Tumors

Over the past 2 weeks, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for acute myeloid leukemia (AML); Fast Track designations for agents in pancreatic cancer and pancreatic/nonpancreatic neuroendocrine tumors; approvals for companion diagnostic tests;...

skin cancer
issues in oncology

Are There Racial Differences in Time to Treatment for Melanoma?

Black patients with stage I to III melanoma are likely to experience a longer delay from diagnosis to surgery than non-Hispanic white patients, according to a study published by Tripathi et al in the Journal of the American Academy of Dermatology. “We already knew that black patients with melanoma...

covid-19

Allocating Ventilators in Times of Crisis: A Brave New World

The unprecedented COVID-19 crisis has challenged us, as a society, to evaluate our core values and philosophy. Ventilators, a precious and limited commodity, are now in short supply. Humanity is at a precipice, and we physicians are facing an ethical dilemma, how best to allocate ventilators, and, ...

Advertisement

Advertisement



Advertisement